178 related articles for article (PubMed ID: 7978857)
1. Molecular and Cell Biological Aspects of Gastroenteropancreatic Neuroendocrine Tumor Disease. Conference proceedings. Berlin, Germany, November 3-7, 1993.
Ann N Y Acad Sci; 1994 Sep; 733():1-535. PubMed ID: 7978857
[No Abstract] [Full Text] [Related]
2. The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms.
Briest F; Grabowski P
Cancer Treat Rev; 2015 May; 41(5):423-30. PubMed ID: 25837868
[TBL] [Abstract][Full Text] [Related]
3. Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors.
Rindi G; Villanacci V; Ubiali A
Digestion; 2000; 62 Suppl 1():19-26. PubMed ID: 10940683
[TBL] [Abstract][Full Text] [Related]
4. Glucose-dependent insulinotropic polypeptide receptors in most gastroenteropancreatic and bronchial neuroendocrine tumors.
Waser B; Rehmann R; Sanchez C; Fourmy D; Reubi JC
J Clin Endocrinol Metab; 2012 Feb; 97(2):482-8. PubMed ID: 22112810
[TBL] [Abstract][Full Text] [Related]
5. Unraveling molecular pathways of poorly differentiated neuroendocrine carcinomas of the gastroenteropancreatic system: A systematic review.
Girardi DM; Silva ACB; Rêgo JFM; Coudry RA; Riechelmann RP
Cancer Treat Rev; 2017 May; 56():28-35. PubMed ID: 28456055
[TBL] [Abstract][Full Text] [Related]
6. [Standardization in pathologic diagnosis of gastrointestinal and pancreatic neuroendocrine tumors].
Zheng J
Zhonghua Bing Li Xue Za Zhi; 2010 Dec; 39(12):793-5. PubMed ID: 21215092
[No Abstract] [Full Text] [Related]
7. Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors.
Asa SL; La Rosa S; Basturk O; Adsay V; Minnetti M; Grossman AB
Endocr Pathol; 2021 Mar; 32(1):169-191. PubMed ID: 33459926
[TBL] [Abstract][Full Text] [Related]
8. Preface: Gastroenteropancreatic system and its tumors: Part 1.
Vinik AI
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):xvii-xviii. PubMed ID: 21095538
[No Abstract] [Full Text] [Related]
9. Site- and grade-specific diversity of LINE1 methylation pattern in gastroenteropancreatic neuroendocrine tumours.
Stricker I; Tzivras D; Nambiar S; Wulf J; Liffers ST; Vogt M; Verdoodt B; Tannapfel A; Mirmohammadsadegh A
Anticancer Res; 2012 Sep; 32(9):3699-706. PubMed ID: 22993308
[TBL] [Abstract][Full Text] [Related]
10. Highlights of the biology of endocrine tumours of the gut and pancreas.
Rindi G; Bordi C
Endocr Relat Cancer; 2003 Dec; 10(4):427-36. PubMed ID: 14713255
[TBL] [Abstract][Full Text] [Related]
11. [Chinese pathologic consensus for standard diagnosis of gastrointestinal and pancreatic neuroendocrine neoplasm].
Chinese Pathologic Consensus Group for Gastrointestinal and Pancreatic Neuroendocrine Neoplasm
Zhonghua Bing Li Xue Za Zhi; 2011 Apr; 40(4):257-62. PubMed ID: 21616002
[No Abstract] [Full Text] [Related]
12. Endocrine precursor lesions of gastroenteropancreatic neuroendocrine tumors.
Klöppel G; Anlauf M; Perren A
Endocr Pathol; 2007; 18(3):150-5. PubMed ID: 18058264
[TBL] [Abstract][Full Text] [Related]
13. Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis.
Duerr EM; Mizukami Y; Ng A; Xavier RJ; Kikuchi H; Deshpande V; Warshaw AL; Glickman J; Kulke MH; Chung DC
Endocr Relat Cancer; 2008 Mar; 15(1):243-56. PubMed ID: 18310291
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive biomarkers in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):155-7. PubMed ID: 23474561
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): what's better?
Milione M
Endocrine; 2018 Jan; 59(1):1-3. PubMed ID: 28417314
[No Abstract] [Full Text] [Related]
16. Molecular aspects of the endocrine tumours of the pancreas and the gastrointestinal tract.
Rindi G; Candusso ME; Solcia E
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S135-8. PubMed ID: 10604117
[TBL] [Abstract][Full Text] [Related]
17. [Gastrointestinal and pancreatic neuroendocrine tumors: a clinicopathologic and immunohistochemical study].
Sun LM; Qiu XS; Wang EH
Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):696-7. PubMed ID: 23302313
[No Abstract] [Full Text] [Related]
18. Oncogene expression in gastroenteropancreatic neuroendocrine tumors: implications for pathogenesis.
Wang DG; Johnston CF; Buchanan KD
Cancer; 1997 Aug; 80(4):668-75. PubMed ID: 9264349
[TBL] [Abstract][Full Text] [Related]
19. AKT inhibition by triciribine alone or as combination therapy for growth control of gastroenteropancreatic neuroendocrine tumors.
Gloesenkamp CR; Nitzsche B; Ocker M; Di Fazio P; Quint K; Hoffmann B; Scherübl H; Höpfner M
Int J Oncol; 2012 Mar; 40(3):876-88. PubMed ID: 22075556
[TBL] [Abstract][Full Text] [Related]
20. An overview of practical issues in the diagnosis of gastroenteropancreatic neuroendocrine pathology.
Chetty R
Arch Pathol Lab Med; 2008 Aug; 132(8):1285-9. PubMed ID: 18684027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
